Inavir meets flu prevention endpoint in Phase III
This article was originally published in Scrip
Australian firm Biota reports that a Phase III prevention study of Inavir (laninamivir octanoate, CS-8958), conducted by Daiichi Sankyo, met its primary endpoint by significantly reducing the transmission of influenza within a household. Daiichi Sankyo intends to apply for approval to market Inavir for the prevention of influenza by the end of the year.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.